Enlivex's Patent Milestone in Japan for Allocetra™
Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a pioneering company in the field of macrophage reprogramming immunotherapy, has recently made significant strides with its latest patent approval journey. The Japanese Patent Office has issued a notice of allowance for a vital patent application titled "THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS" under application number 2022-512861. This patent, once officially issued, is expected to provide substantial intellectual property protection for Enlivex until at least 2040. The company anticipates that the formal issuance of this patent will take place by mid-2025.
Strategic Innovations and CEO Insights
Oren Hershkovitz, Ph.D., the Chief Executive Officer of Enlivex, expressed enthusiasm over the recent notice, stating it underscores their commitment to safeguarding Allocetra™'s commercial opportunities across critical global markets. Dr. Hershkovitz further emphasized that this achievement reflects the company's effective execution of their global intellectual property strategy. He noted, "As we advance, we aim to pursue multiple layers of patent protection in pivotal global markets, aiming to establish Allocetra™ as a breakthrough cell therapy to address osteoarthritis, a pressing medical need currently lacking effective treatment alternatives."
Understanding Knee Osteoarthritis
Knee osteoarthritis stands as the most prevalent form of arthritis, affecting over 32.5 million individuals in the United States alone and an estimated 300 million people globally. Studies indicate that approximately 50% of knees suffering from ACL injuries may develop osteoarthritis within a span of 5 to 15 years. By the year 2040, projections estimate that about 78 million Americans could be afflicted with this condition. In particular, symptomatic knee osteoarthritis has become an escalating issue, with 40% of men and 47% of women likely to develop the condition throughout their lives. The substantial impact of osteoarthritis leads to over a million hospital stays annually in the U.S., primarily due to total joint replacement procedures. The pressing need for effective treatments that alleviate pain and enhance the quality of life for those suffering from osteoarthritis cannot be overstated, especially considering that, at present, there are no FDA or EMA-approved medications that have proven effective in halting or reversing joint damage progression.
The Promise of Allocetra™ in Immunotherapy
Enlivex is on the forefront of developing Allocetra™, which is characterized as a universal, off-the-shelf cell therapy intended to reprogram macrophages into their homeostatic state. This critical process is essential for the rebalancing of the immune system and can significantly mitigate life-threatening conditions. Allocetra™ aims to reset non-homeostatic macrophages, potentially offering hope and improved outcomes for patients suffering from osteoarthritis. The innovative approach by Enlivex reflects a transformative effort towards battling the challenges posed by this chronic condition.
Contact Information for Inquiries
For further information about Enlivex Therapeutics, individuals are encouraged to reach out to:
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
Email: shachar@enlivexpharm.com
Investor Relations Contact
Dave Gentry, CEO
RedChip Companies Inc.
Phone: 1-407-644-4256
Email: ENLV@redchip.com
Frequently Asked Questions
What recent development did Enlivex announce?
Enlivex announced a notice of allowance for a patent related to Allocetra™ for treating osteoarthritis in Japan.
What is Allocetra™?
Allocetra™ is a universal cell therapy designed to reprogram macrophages and address various immune-related conditions.
Why is osteoarthritis significant in this context?
Osteoarthritis is a common and debilitating condition with limited treatment options, highlighting the need for innovative therapies like Allocetra™.
When is the patent for Allocetra™ expected to be formally issued?
Enlivex anticipates the formal issuance of the patent in the second quarter of 2025.
What is the duration of the intellectual property protection for this patent?
Once issued, the patent will provide protection for Enlivex until at least 2040.
